Literature DB >> 15877236

Glycosaminoglycans in childhood urinary tract infections.

Nurcan Cengiz1, Esra Baskin, Ruksan Anarat, Pinar Isik Agras, Selman Vefa Yildirim, Filiz Tiker, Ali Anarat, Umit Saatci.   

Abstract

It has been suggested that urinary glycosaminoglycans (GAGs) form a natural defense mechanism against urinary tract infections (UTIs). This study investigated whether urinary GAGs play a role in pediatric UTIs, and whether urinary GAG level can be used to differentiate upper UTI from lower UTI. Forty-one children with UTIs (33 girls and eight boys; mean age 5.4+/-3.7 years) and 46 age- and sex-matched healthy children (35 girls and 11 boys; mean age 6.6+/-3.9 years) were included in the study. Urinary GAG levels were measured at the onset of acute infection and after a 10-day course of antibiotic treatment. Group GAG findings were compared, and comparisons were also made with the patients divided according to sex and according to UTI type (upper versus lower). The mean urinary GAG level in the patient group at the onset of acute infection (pretreatment) was significantly higher than the mean level in the control group (132.2+/-104.8 mg/g vs 42.2+/-27.1 mg/g creatinine, respectively; P <0.01). In the patient group, the mean urinary GAG level after antimicrobial therapy was significantly lower than the pretreatment level (75.9+/-52.1 mg/g vs 132.2+/-104.8 mg/g creatinine, respectively; P <0.01). However, the mean post-treatment level was still higher than the mean level in the controls ( P <0.05). There was no significant difference in urinary GAG levels when patients were categorized as upper versus lower UTI ( P >0.05). The study results suggest that GAGs play an important role in the pathogenesis of UTIs in children, and that measurement of urinary GAGs may be a valuable noninvasive method for evaluating UTIs in this patient group. However, this assay cannot be used to differentiate upper UTI from lower UTI in children.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877236     DOI: 10.1007/s00467-005-1856-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  Simple spectrophotometric quantification of urinary excretion of glycosaminoglycan sulfates.

Authors:  G Panin; S Naia; R Dall'Amico; L Chiandetti; F Zachello; C Catassi; L Felici; G V Coppa
Journal:  Clin Chem       Date:  1986-11       Impact factor: 8.327

Review 2.  Pathogenesis of urinary tract infections. Bacterial adherence, bladder defense mechanisms.

Authors:  C L Parsons
Journal:  Urol Clin North Am       Date:  1986-11       Impact factor: 2.241

3.  Urinary glycosaminoglycan excretion as a laboratory marker in the diagnosis of interstitial cystitis.

Authors:  R E Hurst; C L Parsons; J B Roy; J L Young
Journal:  J Urol       Date:  1993-01       Impact factor: 7.450

4.  Bladder mucin: a scanning electron microscopy study in experimental cystitis.

Authors:  M J Balish; J Jensen; D T Uehling
Journal:  J Urol       Date:  1982-11       Impact factor: 7.450

5.  Bladder surface glycosaminoglycans is a human epithelial permeability barrier.

Authors:  J D Lilly; C L Parsons
Journal:  Surg Gynecol Obstet       Date:  1990-12

6.  Natural history of interstitial cystitis in 274 patients receiving sulfated polysaccharide therapy.

Authors:  N J Ho; J A Koziol; C L Parsons; W Barlow; N S Weiss
Journal:  Urology       Date:  1999-06       Impact factor: 2.649

7.  Glycosaminoglycans excretion in interstitial cystitis.

Authors:  T Akçay; D Konukoğlu
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

8.  Prevention of urinary tract infection by the exogenous glycosaminoglycan sodium pentosanpolysulfate.

Authors:  C L Parsons
Journal:  J Urol       Date:  1982-01       Impact factor: 7.450

9.  Urinary glycosaminoglycan levels following induced cystitis in monkeys.

Authors:  D T Uehling; E Kelley; W J Hopkins; E Balish
Journal:  J Urol       Date:  1988-05       Impact factor: 7.450

10.  Urinary excretion of glycosaminoglycans in urological disease.

Authors:  B Baggio; G Gambaro; E Cicerello; S Mastrosimone; G Marzaro; A Borsatti; F Pagano
Journal:  Clin Biochem       Date:  1987-12       Impact factor: 3.281

View more
  3 in total

1.  Fluorescent liposomes for differential interactions with glycosaminoglycans.

Authors:  Erin K Nyren-Erickson; Manas K Haldar; Yan Gu; Steven Y Qian; Daniel L Friesner; Sanku Mallik
Journal:  Anal Chem       Date:  2011-06-30       Impact factor: 6.986

2.  Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease.

Authors:  J de Ruijter; L Ijlst; W Kulik; H van Lenthe; T Wagemans; N van Vlies; F A Wijburg
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

3.  Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study.

Authors:  Shucheng Liu; Ying Yu; Yang Gao; Xiong Yang; Zili Pang
Journal:  Urolithiasis       Date:  2015-08-05       Impact factor: 3.436

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.